Study to look at the effectiveness, tolerability and safety of two doses of Rasagiline (0.5 mg and 1mg) in advanced Parkinson's Disease (PD) Patients who have been treated with Levodopa/Carbidopa therapy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
254
0.5 rasagiline mesylate
1.0 mg rasagiline mesylate
Margolin Brain Institute
Fresno, California, United States
Emory University
Atlanta, Georgia, United States
Rush - Presbyterian St. Luke's Medical Center
Chicago, Illinois, United States
Creighton University
Omaha, Nebraska, United States
long-term safety and tolerability of rasagiline
To evaluate the long-term safety and tolerability of rasagiline in PD patients with motor fluctuations treated with chronic levodopa/carbidopa (LD/CD) or levodopa/benserazide (LD/BZD) therapy.
Time frame: 6 months
long- term clinical effect of rasagiline
To assess the long- term clinical effect of rasagiline on the course of the disease.
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Long Island Jewish Medical Center
New Hyde Park, New York, United States
University of Rochester
Rochester, New York, United States
Pennsylvania Hospital
Philadelphia, Pennsylvania, United States
CHUM-Hotel-Dieu
Montreal, Quebec, Canada